Dr. Nancy Ann Dawson, MD

Dr. Dawson practices at Medstar Georgetown Medical Center in Washington, District of Columbia.

Dr. Dawson's NPI, 1073571519, was assigned on May 3, 2006. Dr. Dawson graduated from Georgetown University School Of Medicine in 1979. Dr. Dawson holds District of Columbia license MD036496.

Dr. Dawson's primary practice is Medstar Georgetown Medical Center, at 3800 Reservoir NW Rd, Washington, DC 20007 in District Of Columbia County. The practice phone is (202) 444-1400.

Dr. Dawson's primary practice is Medstar Georgetown Medical Center in Washington, District of Columbia. Dr. Dawson is also affiliated with MedStar Washington Hospital Center. The medical group on file is MedStar Medical Group. Dmand AI also links Dr. Dawson to 2 more hospitals and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dawson practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dawson's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dawson is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Dawson's licenses on file in 3 states: District of Columbia, Maryland and Virginia.

Dmand AI lists breast cancer, colorectal cancer, multiple myeloma and prostate cancer among the conditions Dr. Dawson treats.

CMS data shows 1,172 Medicare services from Dr. Dawson across 5 procedure codes in 2024, for 271 Medicare patients. Medicare paid $114,531 for them.

CMS counts 271 Medicare patients who saw Dr. Dawson in 2024. The largest group is 75 to 84, with 120 patients. 75% of them have cancer, and 75% have high blood pressure. 6% are also on Medicaid. Their average risk score is 1.97, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dawson's median patient age at 72, with 5% women.

In 2024, Dr. Dawson wrote 1,399 Medicare Part D claims for 146 patients. 42% of them were for generic drugs. CMS names the drug for 1,273 of them, across 19 drugs with 11 or more claims each, at $6,637,958 in total drug cost. In 2023, CMS named 845 claims across 18 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 83 out of 100 for Dr. Dawson for performance year 2024, reported as part of a group. Dr. Dawson accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dawson as offering telehealth.

Dmand AI links 102 papers to Dr. Dawson, published from 2008 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Prostatic Neoplasms, Prostate-Specific Antigen and Antineoplastic Agents. Dr. Dawson has published most often in J Clin Oncol. Dr. Dawson's most frequent co-authors are Sean Collins, MD, Deepak Kumar, MD and Paul Denis Leger, MD.

Dmand AI links Dr. Dawson to 12 clinical trials, 6 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Prostatic Neoplasms, Prostatic Diseases and Carcinoma, Renal Cell. National Cancer Institute (NCI) sponsors the most, 2.

CMS Open Payments shows 2,175 general payments to Dr. Dawson from 25 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 73% of the total. Janssen Pharmaceuticals, Inc paid the most, $426,331. It also lists 3 research payments totaling $4,470 from 2024 to 2025.

Dmand AI lists 5 awards for Dr. Dawson, most recently America's Top Doctors in 2014.

Dr. Dawson graduated from Georgetown University School Of Medicine in 1979.

Dr. Dawson is in network with 16 carriers, including Elevance, Excellus BlueCross BlueShield and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.